CJC-1295 101: A Plain-English Guide for 2026

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

Most people land on a CJC-1295 page because they're weighing it against another option, trying to manage side effects, or trying to figure out if it's worth the money. We try to answer all three honestly here. The headline: Increased mean GH and IGF-1 levels in early-phase human studies.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) version binds albumin to extend its half-life from minutes to days.

There is no single FDA-licensed manufacturer of CJC-1295 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. CJC-1295 is not currently approved by the FDA for general human use. Available evidence comes from early-phase clinical work. We do not endorse self-administration of unapproved compounds.

The drug class long-acting ghrh analog (research peptide) works by targeting specific receptor pathways. Let's walk through what that means in practice.

How CJC-1295 Works in the Body

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) version binds albumin to extend its half-life from minutes to days. The receptor target — compound-specific — drives the downstream effects users care about: increased mean gh and igf-1 levels in early-phase human studies.

The pharmacokinetics matter for daily use. CJC-1295 has a half-life of approximately 6-8 days (DAC version); ~30 minutes (no-DAC version), which determines how often it is dosed. The standard route of administration is subcutaneous injection (research use), and the typical schedule is varies; once weekly (DAC) or daily (no-DAC) in user protocols.

For more detail on the underlying biology, see our breakdown of how CJC-1295 works.

Who Uses CJC-1295?

CJC-1295 is most relevant for people whose situation maps to its approved indications: none in the US.

People who should avoid CJC-1295 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of CJC-1295 include:

• injection-site reactions
• transient flushing
• headache

Serious risks — uncommon but worth knowing — include:

• fluid retention
• carpal tunnel symptoms
• potential effect on glucose metabolism
• supply-chain contamination from unregulated suppliers

We have a more detailed breakdown in our CJC-1295 side-effects guide.

CJC-1295 vs Alternatives

FDA-approved GHRH analogs include sermorelin (limited availability) and tesamorelin (HIV-associated lipodystrophy). Recombinant human growth hormone is the standard for diagnosed GH deficiency. If you are weighing CJC-1295 against another option, our comparison pages include CJC-1295 Side Effects: The Complete List and How to Handle Them, Does CJC-1295 Really Work? An Evidence-Based Results Review, The Real CJC-1295 Price Tag in 2026 — With and Without Insurance.

Bottom Line

Treat CJC-1295 as one tool among several. The most successful users we see treat it as part of a structured approach, not a standalone fix. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering CJC-1295, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• CJC-1295 Side Effects: The Complete List and How to Handle Them
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• CJC-1295 Cycles Explained: Where the Evidence Stops
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.